Pfizer has announced positive top-line results from a comparative, confirmatory safety and efficacy study of an investigational bevacizumab biosimilar referenced on Avastin.
Pfizer has announced positive top-line results from a comparative, confirmatory safety and efficacy study of an investigational bevacizumab biosimilar referenced on Avastin. The trial demonstrated equivalence between the reference bevacizumab and Pfizer's PF-06439535 in terms of objective response rate in patients with advanced non-squamous non-small cell lung cancer (NSCLC).
The REFLECTIONS B7391003 study, a comparative, randomized, double-blind clinical trial, included 719 patients. The study sought to evaluate the efficacy, safety, pharmacokinetics (PK), and immunogenicity of PF-06439535 administered together with carboplatin and paclitaxel compared with the same characteristics of the reference bevacizumab administered with carboplatin and paclitaxel in first-line treatment of patients with advanced non-squamous NSCLC. The study met its primary endpoint of demonstrating equivalent objective response rate, defined as the proportion of patients with a reduction in tumor size of a predefined amount for a minimum time period.
“We are encouraged by this data, and its importance in helping to advance physician confidence in, and understanding of, the potential value of biosimilar medicines for cancer patients around the world,” said Salomon Azoulay, MD, senior vice president and chief medical officer of Pfizer Essential Health. “As Pfizer’s second proposed oncology monoclonal antibody biosimilar to achieve positive top line data results, we continue to focus on and commit to advancing our pipeline of proposed biosimilars, with the goal of expanding patient access to these important therapeutic options.”
The promising results are welcome news for Pfizer, which suffered a setback to its biosimilars program earlier this year; in June, the FDA issued the drug maker a second complete response letter (CRL) for its biosimilar epoetin alfa (referenced on Epogen and Procrit), citing concerns related to the company’s manufacturing plant.
In addition to its troubled epoetin alfa and its PF-06439535, Pfizer reports an additional 4 biosimilar candidates in its late-stage pipeline; the drug maker is developing a biosimilar adalimumab (referenced on Humira), infliximab for commercialization in markets outside the European Economic Area (referenced on Remicade), rituximab, (referenced on Rituxan, MabThera), and trastuzumab (referenced on Herceptin).
Less enthusiastic about the bevacizumab study’s results, however, may be reference biologic maker Roche, which earned $6.75 billion in sales of Avastin in 2016. Roche already suffered a setback this month when the FDA’s Oncologic Drugs Advisory Committee (ODAC) unanimously recommended approval of another biosimilar candidate, Amgen’s ABP 215. Regulatory action on Amgen's biosimilar bevacizumab product is expected in September.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.